Skip to Content

Korlym Approval History

FDA Approved: Yes (First approved February 17, 2012)
Brand name: Korlym
Generic name: mifepristone
Dosage form: Tablets
Company: Corcept Therapeutics
Treatment for: Cushing's Syndrome

Korlym (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance.

Development History and FDA Approval Process for Korlym

DateArticle
Feb 17, 2012Approval FDA Approves Korlym for Patients with Endogenous Cushing's Syndrome

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide